HB Wealth Management’s SAB Biotherapeutics SABS Stock Holding History

HB Wealth Management’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$975K	Buy	307,717 +217	+0.1%	+$789	0.01%	865
2026 Q2	$1.2M	Hold	307,500	–	–	0.01%	669
2026 Q1	$1.18M	Hold	307,500	–	–	0.01%	604
2025 Q4	$1.15M	Hold	307,500	–	–	0.01%	581
2025 Q3	$618K	Buy	+307,500	New	+$695K	﹤0.01%	772
2025 Q2	–	Sell	-263,200	Closed	-$358K	–	1276
2025 Q1	$358K	Buy	263,200 +25,800	+11%	+$59.2K	﹤0.01%	891
2024 Q4	$982K	Buy	237,400 +128,800	+119%	+$423K	0.01%	416
2024 Q3	$293K	Buy	+108,600	New	+$301K	﹤0.01%	769

Other funds holding SABS

Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Polymer Capital Management (HK) Hong Kong $1.06B AUM 138.97% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $96.6B AUM 22.52% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

HB Wealth Management's SABS Position: Q3 2026 in Review

HB Wealth Management increased its SAB Biotherapeutics (SABS) stake by 0.07% in Q3 2026, buying an estimated $789 and bringing the position to 307,717 shares worth $975K. The position accounts for 0.01% of the portfolio, ranked #865.

HB Wealth Management first reported a position in SABS in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.2M in Q2 2026. 45 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

HB Wealth Management held 307,717 shares of SAB Biotherapeutics worth $975K as of Q3 2026.
HB Wealth Management bought 217 SAB Biotherapeutics shares in Q3 2026, an estimated $789.
SAB Biotherapeutics made up 0.01% of HB Wealth Management's portfolio in Q3 2026, its #865 holding.
HB Wealth Management first reported a position in SAB Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
HB Wealth Management's SAB Biotherapeutics position peaked at $1.2M in Q2 2026.
45 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on HB Wealth Management's 13F filing for Q3 2026, filed 23 Oct 2026.